KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Short term Debt (2023 - 2025)

Rigel Pharmaceuticals has reported Short term Debt over the past 3 years, most recently at $29.8 million for Q4 2025.

  • Quarterly results put Short term Debt at $29.8 million for Q4 2025, up 309.96% from a year ago — trailing twelve months through Dec 2025 was $29.8 million (up 309.96% YoY), and the annual figure for FY2025 was $29.8 million, up 309.96%.
  • Short term Debt for Q4 2025 was $29.8 million at Rigel Pharmaceuticals, roughly flat from $29.8 million in the prior quarter.
  • Over the last five years, Short term Debt for RIGL hit a ceiling of $29.8 million in Q4 2025 and a floor of $7.2 million in Q4 2023.
  • Median Short term Debt over the past 3 years was $14.8 million (2025), compared with a mean of $18.0 million.
  • Peak annual rise in Short term Debt hit 309.96% in 2025, while the deepest fall reached 0.24% in 2025.
  • Rigel Pharmaceuticals' Short term Debt stood at $7.2 million in 2023, then grew by 0.59% to $7.3 million in 2024, then surged by 309.96% to $29.8 million in 2025.
  • The last three reported values for Short term Debt were $29.8 million (Q4 2025), $29.8 million (Q3 2025), and $22.4 million (Q2 2025) per Business Quant data.